Journal of Blood Disorders & Transfusion

Do Chronic Hypnotics Users Truly Develop Tolerance?

Amit Green^*, Merav Bensky, Lilach Kemer, Orit Stein and Yaron Dagan Department of Otolaryngology, Hebrew University, Jerusalem, Israel
^*Correspondence: Amit Green, Department of Otolaryngology, Hebrew University, Jerusalem, Israel, Tel: 525775111, Email:

Received: 08-Jun-2021 Published: 29-Jun-2021, DOI: 10.35248/2155-9864.21.12.467

Introduction

Insomnia is the most common sleep disorder in the general adult population, with about 25% of adults stating they are dissatisfied with their sleep and 10–15% reporting symptoms of insomnia associated with daytime consequences. According to the third edition of the International Classification of Sleep Disorders (ICSD-3), insomnia is characterized by difficulty in initiating sleep, maintaining sleep continuity, or poor sleep quality. If symptoms have persisted for less than three months it is considered short-term insomnia. For some individuals, sleep disturbance can persist for a long period of time, even after the initial cause has disappeared. Persistent or chronic insomnia refers to those patients who suffer from the clinical symptoms for more than 3 months. The prevalence of chronic insomnia in industrialized nations is estimated to be 5-10%4. Results of longitudinal studies show that nearly 70% of individuals with insomnia at baseline continue to report insomnia a year later, and 50% still have insomnia up to 3 years later [1]. Insomnia adversely affects quality of life and health, as well as academic performance and work productivity of affected individuals. It increases the risk for car accidents, presenting with more irritability and an increase in daytime sleepiness.

Insomnia is considered to be a contributing risk factor for cardiovascular diseases, chronic pain syndromes, depression, anxiety, diabetes, obesity, and asthma. In addition, insomnia is associated with increased health care utilization and elevated morbidity, and decreased quality of life and daily function. Several variables were reported to be associated with higher rates of insomnia: female gender, older age, mental illness, insomnia in the past, and comorbid illness. Moreover, since insomnia impairs the quality of life of one-tenth of the adult population, it also poses a substantial economic burden on society by affecting the workplace productivity [2].

Treating insomnia is therefore highly important due to a positive effect on the individual's health and quality of life, and is also cost effective. Treatment options for insomnia include. Sleep hygiene treatment educating and guiding the patients for healthy lifestyle. Relaxation techniques such as Guided Imagery, Yoga, breathing exercise, and meditation. Cognitive Behavioral Therapy for insomnia (CBTi). Pharmacological treatment: The use of hypnotics Benzodiazepines (BZD) and Benzodiazepine Receptor Agonists (BzRA) to treat insomnia is common.

Tolerance to a pharmaceutical treatment is defined as a reduction in certain pharmacological effects of a drug on repeated exposure to a given dose or the need to increase the amount of drug intake to obtain the same effect. Several clinical trials in humans reported rapid tolerance to the sleep-promoting effects of BZD after repeated administrations. Therefore, physicians are frequently apprehensive about chronic use of hypnotics, and it is generally advocated that this treatment should be limited to no more than four weeks, or avoided. In general, BDZs are considered to be safe and effective in the short term. Long-term use has been suspected to result in tolerance, dependence, and rebound insomnia upon discontinuation, but it is important to note that the quality of the data in these studies is weak. However, two uncontrolled open-label studies, one with zolpidem and another with zaleplon, have shown these medications may be effective for 3 to 6 months without dose escalation and tolerance [3]. Moreover, clinical studies designed to assess the efficacy of BzRA failed to find tolerance following repeated administrations. According to rush, there is some evidence to suggest that the tolerance and dependence-producing effects of zolpidem, a BzRA hypnotic, may be less than those of benzodiazepines.

A major issue regarding the use of hypnotic agents for chronic insomnia is the safe duration of hypnotic treatment. Insomnia disorder often lasts months or years; however, there have been relatively few long-term, randomized controlled studies performed to assess long-term treatment with sleep-promoting medications. Results from studies conducted with eszopiclone, zolpidem, and ramelteon in adults taking the medications for a 3-6 month period show continued efficacy with no rebound insomnia, tolerance, or residual daytime effects.

There is insufficient data at this time to determine the efficacy and safety of long-term hypnotic treatment. The european guideline for the diagnosis and treatment of insomnia states. "Long-term treatment of insomnia with BZ or BZRA is not generally recommended because of a lack of evidence and possible side-effects". Meaning that after major and comprehensive review of available data there is still uncertainty about the efficacy and safety of long-term use of hypnotic medication for insomnia. We find this inconsistency in the literature regarding the existence of tolerance to chronic hypnotic use for insomnia to be a major problem in clinical practice. Therefore, the aim of our study is to assess the development of tolerance to chronic hypnotic administration in patients with insomnia [4]. An additional aim is to describe the prevalence of hypnotic treatment among patients with insomnia in Israel.

Methods and Materials

Study population and database

This is a retrospective analysis of data from the computerized pharmacy records of Maccabi Health Services (MHS), the second largest Health Maintenance Organization (HMO) in Israel, insuring roughly 1.6 million members over 18 years old. Maccabi Health Care Services has had a cumulative reliable and quality-controlled database. This database is highly reliable and contains all physician visits, all prescribed medications, and over 98% of all patient diagnoses. The Maccabi Health Services national pharmacy database is a very well-managed database containing full annotation of every prescription dispensed by MHS, with details on class of medication, generic name, commercial name, and dosage. This data is combined with other MHS databases including the demographic database and the health and illnesses status of all MHS insures. Data were collected for all patients over the age of 18 years who were prescribed with hypnotics [5]. The use of the following medications was sought: benzodiazepines: Brotizolam, lorazepam, clonazepam, Nitrazepam, and flunitrazepam; BzRA drugs: zolpidem and zopiclone (eszopiclone and Zaleplon are not in use in Israel). Data collected included. Demographic details: age, gender. Data regarding hypnotics consumption: duration of consumption in treatment days per year, consumption distribution according to medication group type (benzodiazepine and BzRA).

Three groups were defined: occasional, chronic, and long-term chronic users. Occasional usage of hypnotics was defined as consuming or purchasing fewer than 180 sleeping pills per year. Chronic usage of hypnotics was defined as purchase of 180 or more sleeping pills per year. Long-term chronic usage was defined as purchase of 180 or more sleeping pills for four consecutive years. In addition, we defined an increase or decrease of hypnotic usage as change of 30 or more sleeping pills. Since our observation was based on a pharmacy database, we chose to use this definition for chronic usage, assuming that purchase of 180 sleeping pills per year reflects a constant and routine use of hypnotics. The long-term chronic usage definition reflects chronic and prolonged usage for four consecutive years of hypnotic's consumption [6]. The decision to use thirty sleeping pills to define a change in consumption of hypnotics was made to reflect one month’s worth of additional or reduced treatment time per year.

Statistical analyses and ethical issues

No names or personal identity details were included in the database. The study was approved by the ethics committee of Maccabi Health Services. Data were analyzed using SPSS software version. The statistics consisted of predominantly descriptive statistics and comparative analyses (ANOVA) between the various periods or groups. p<0.05 was considered statistically significant [7].

Results

Characteristics of chronic and occasional users

Our data show (Table 1) a minor and insignificant increase in the mean number of consumed sleeping pills in the occasional and chronic user groups between 2011 and 2014. We observed a negligible increase of two pills in the occasional users between 2011 and 2014 and only eight pills for the whole time period in the chronic user's group [8]. Moreover, the mode index was not changed between the years 2011-2014 and was 360 in the chronic users and 30 sleeping pills for the occasional group (Table 1).

Table 1: The central tendencies indexes and STD for occasional and chronic users, number and percentage of chronic and occasional users, type of treatment, and demographic data 2011-2014.

Our results revealed that the number of chronic users is increasing gradually each year, with nearly three thousand patients added to the chronic user's group. This is an increase of 2.5% each year from 16.6% to 24.3% between 2011 and 2014. It

Two thirds of the chronic users were female, showing that the majority of chronic users are women. Forty-two percent of the chronic users use benzodiazepine type of hypnotics, approximately 30% use BzRA, and 28% use both type of hypnotics. The type of hypnotic medication taken by chronic users did not change over time according to our data [9]. We observed an increase in the prevalence of chronic users in the two youngest age groups, with a decreased percentage in the oldest age group, and almost no change in the 65-75 years age group. In summary, the number of chronic users is increasing each year, the majority of them are women and they are younger, but we did not notice an increase in the number of sleeping pills taken per chronic user.

Table 2 presents the number of occasional and chronic patients in 2011 and 2014. According to our data, in 2011, 102,131 patients (83.4%) were occasional users and 20,365 (16.6%) were chronic users. In 2014, the number of occasional users decreased to 92,669 patients (75.7%), and the number of chronic users increased to 29,827 patients (24.3%). These results show that between 2011 and 2014 only 7.9% were added to the chronic user's group. In addition, we explored the transition between the groups during the study years [10]. We found that 88,395 patients (72.2%) were occasional users in 2011 and remained occasional users in 2014, while 16,091 (13.1%) patients were chronic users in 2011 and remained chronic users in 2014. However, of the 14.7% who changed their usage status, 13,736 patients (11.2%) who were occasional users in 2011 became chronic users in 2014, while 4,274 patients (3.5%) who were chronic users in 2011 became occasional users or quit the pharmacology treatment in 2014 (Table 2).

Table 2: Number of occasional and chronic users in 2011 and 2014.

Trends in consumption of hypnotics among long-term chronic users

According to our data, (11.8%) met our definition of long-term chronic users–meaning they have purchased 180 or more sleeping pills per year each year between 2011 and 2014. Table 3 presents the change trends in hypnotics usage in the long-term chronic users between 2011 and 2014. The majority of the patients (53.5%) either did not change (23.8%) or decreased (29.7%) the number of sleeping pills they consumed, while only 46.5% of the long-term chronic user patients increased the number of sleeping pills used. It is important to note that only 5.5% (6721 of 122,496) of the long-term chronic users have increased the quantity of sleeping pills used during the four-year period studied (Table 3).

Table 3: Number and the percentage of patients that increased, decreased, or did not change the number of sleeping pills between 2011 and 2014.

Discussion

Main findings

Our study provides a database analysis of four years of use of hypnotic medications in the second largest health service provider in Israel with more than two million members. First, the majority of hypnotic medication users are occasional. Second, we noticed that among the chronic users, each year quite a few became occasional users or quit using hypnotics. Our results revealed that although more insomnia patients are treated chronically with pharmaco-therapy they apparently do not develop tolerance, as the pattern of usage of these patients is usually one pill per night [11]. We report that age is correlated with escalation of hypnotic usage, and that the majority of users are women–about two-fold compared to men.

In our study 7.6% of the general population used hypnotic medication at least once during the study years. This is slightly higher than reported in a UK study and nearly the same as reported in a recent study in Germany. Only 1.9% of the population was defined as chronic users, according to our definition. Our results support the notion that the majority of hypnotic medication users are occasional users; only one in five was defined as a chronic user and only one in nine can be defined as a long-term chronic user. This result is in line with a recently published epidemiological study using a comparable definition of chronic usage.

The majority of chronic users (two out of three) were women. This result is in line with previous study reporting similar results. Chronic patients have a tendency to use benzodiazepine type of hypnotics, while BzRA type was used by 30% and the rest (28%) used both types of hypnotics. We didn't observe gender or type of hypnotic medication effect on the consumption of sleeping pills. A positive correlation was found between advanced age and an increase in hypnotics purchased, similar relation was reported.

Our results revealed that chronic patients do not increase their consumption of hypnotic medication over time. This finding challenges the common concept in the general population and among physicians that chronic usage of hypnotics leads to development of tolerance. We noticed that an increase in consumption of hypnotic medication is occurring only in the first year, with no further increase in the following years. This pattern, of increase in the first year only, was reported previously in a comparable study that explored the pattern of purchased hypnotics in Israel. We believe that this pattern of increase in the purchase of hypnotics during the first year is the result of dose titration increased dose until reaching therapeutic effect, or the need to change the type of medication used due to sideeffects or ineffectiveness. Additional support to our idea comes from the central indexes (median and mode in our study), presenting a constant value of 360 sleeping pills per year reflecting usage of one pill per night among chronic users over a prolonged period of time.

We report an increase of 8% in the number of chronic users between 2011 and 2014, an average increase of 2% per a year. When we check the cross-over of patients between groups, occasional vs. chronic, we found that for every 3 occasional users who became chronic users we can find one chronic user who became an occasional user. To the best of our knowledge, this study is the first to report this, as studies usually focus on the rate and number of patients that become chronic users with no reporting of the rate of chronic users that become occasional. This finding challenges the fundamental fear and belief that a newly diagnosed insomnia patient who starts using hypnotics will eventually become a chronic user and dependent on the treatment. Our retrospective data with large numbers of chronic patients over the long-term follow-up found that there are many chronic users that become non-chronic and even quit treatment with hypnotics. In addition, an important finding is the change in the proportion of patients in the healthcare system that is chronic users; this might suggest changes in prescribing patterns of hypnotics [12].

The majority of the long-term chronic users of hypnotic medications did not increase the number of sleeping pills purchased during the study period, which suggests that they did not increase their use of sleeping pills during the study period. It is important to note that although nearly one in two long-term chronic patients did increase the number of hypnotic pills used between 2011 and 2014, this group of patients' numbers only about 6000, nearly 5.5% of the general population of patients that uses hypnotic medications. In other words, if one is a newly diagnosed patient suffering from insomnia and begins to consume hypnotics, their odds to become a chronic user that develops tolerance is only 5%. This is a key point in our study, as many insomnia patients as well as their treating physicians are hesitant to begin treatment for insomnia with hypnotic medication due to fear of tolerance. Riemann18 state that: "It is undisputed that BZ and BZRA have a potential for tolerance and dependency. However, there are little data available on the number of patients who will become dependent when taking BZ or BZRA for certain period of time". Our results show that the probability to develop tolerance is rare and usually happened under long-term consumption of hypnotics. A further support to our claim comes from pharma-physiological studies, in which tolerance to hypnotics is explained by downregulation of the receptor as the aftermath of neuroplasticity. However, it is demonstrated that even after chronic administration of benzodiazepines, the number of benzodiazepine sites does not decrease, nor does the sensitivity of the benzodiazepine site.

Our study has several limitations. First, it was a retrospective pharmacy database study and not a prospective controlled clinical trial. However, there is evidence that hypnotics that are bought are usually used. This suggests that hypnotic purchases recorded in the pharmacy data base of MHS is a good proxy for actual medication use. Moreover, this retrospective study method allows us to collect data from more than 100,000 patients over a long time period. Second, several definitions for chronic hypnotic medication usage were previously applied and there is a lack of standardization in the literature, which makes comparing between studies difficult. We addressed this issue by using two different definitions of chronicity chronic and longterm chronic use. Our definitions of chronic and long-term chronic use are very rigorous definitions of chronic usage of hypnotics, allowing us to explore the effects of consumption hypnotics over a long time period and their effects on insomnia patients.

Conclusion

Data of surveys done from 1979 to 2002 in several urban and rural places of Bali have revealed that STH infection was endemic both in adult people and children especially in elementary school children. Surveys carried out from 2002 to 2010 at several elementary schools in rural villages in Badung and Gianyar district have found Ascaris prevalence of 21.9%-76.6%, Trichuris prevalence of 12.0%-83.5%%, and hookworm prevalence of 0% to 13%. Intensity of infection of Ascaris and Trichuris in elementary schoolchildren was mostly light to moderate but still a portion of them had heavy intensity. Treatment with pyrantel proved to be effective for Ascaris and hookworm infection but not as effective for Triichuris infection; Albendazole was very effective for Ascaris and hookworm and moderately effective for Trichuris infection. Although the overall level of latrine ownership in households in Bali has increased in the last decade, still many of households in rural villages do not possess latrines due to economic handicaps that make many people have to defecate indiscriminately, thus causing contamination of soil with infective STH eggs that act as source of infection. We believe that sustained and regular anthelmintic treatment and health education for schoolchildren in known endemic villages combined with provision of latrines and safe water supply for households, despite its demanding a big investment, should be crucially undertaken by the provincial and central government in order to significantly reduce or eliminate STH infection in the community, in particular among elementary schoolchildren.

REFERENCES

1. Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123–130
2. Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97–111.
3. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.
4. Ohayon MM. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the international classification of sleep disorders (ICSD). Sleep Med. 2009;10(9):952–960.
5. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: A longitudinal study in a UK population. Sleep. 2007;30(3):274–280.
6. Morin CM, Bélanger L, LeBlanc M, Lvers H, Savard J, Espie CA, et al. The natural history of insomnia: A population-based 3-year longitudinal study. Arch Intern Med. 2009;169(5):447–453.
7. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39(6):411–418.
8. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Basta M, et al. Insomnia with short sleep duration and mortality: The penn state cohort. Sleep. 2010;33(9):115–164.
9. Xu M, Bélanger L, Ivers H, Guay B, Zhang J, Morin CM, et al. Comparison of subjective and objective sleep quality in menopausal and non-menopausal women with insomnia. Sleep Med. 2011;12(1):65-69.
10. Rybarczyk B, Lund HG, Garroway AM, Mack L. Cognitive behavioral therapy for insomnia in older adults: Background, evidence, and overview of treatment protocol. Clin Gerontol. 2013;36(1):70-93.
11. Kessler RC, Berglund PA, Coulouvrat C, Hazak G, Roth T, Shahly T, et al. Insomnia and the performance of US workers: Results from the America insomnia survey. Sleep. 2011;34(9):1161-1171.
12. Dement WC. The proper use of sleeping pills in the primary care setting. J Clin Psychiatry. 1992;53:50–56.